Adenovirus vectors for gene therapy, vaccination and cancer gene therapy.

Adenovirus vectors are the most commonly employed vector for cancer gene therapy. They are also used for gene therapy and as vaccines to express foreign antigens. Adenovirus vectors can be replication-defective; certain essential viral genes are deleted and replaced by a cassette that expresses a foreign therapeutic gene. Such vectors are used for gene therapy, as vaccines, and for cancer therapy. Replication-competent (oncolytic) vectors are employed for cancer gene therapy. Oncolytic vectors are engineered to replicate preferentially in cancer cells and to destroy cancer cells through the natural process of lytic virus replication. Many clinical trials indicate that replication-defective and replication-competent adenovirus vectors are safe and have therapeutic activity.

[1]  K. Partanen,et al.  Treatment of cancer patients with a serotype 5/3 chimeric oncolytic adenovirus expressing GMCSF. , 2010, Molecular therapy : the journal of the American Society of Gene Therapy.

[2]  M. Liang.  Clinical development of oncolytic viruses in China. , 2012, Current pharmaceutical biotechnology.

[3]  R. DeBiasi,et al.  Eradication of disseminated adenovirus infection in a pediatric hematopoietic stem cell transplantation recipient using the novel antiviral agent CMX001. , 2011, Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology.

[4]  A. Heim,et al.  Prevalence, quantification and typing of adenoviruses detected in river and treated drinking water in South Africa , 2005, Journal of applied microbiology.

[5]  Malcolm K. Brenner,et al.  Identification of Hexon-Specific CD4 and CD8 T-Cell Epitopes for Vaccine and Immunotherapy , 2007, Journal of Virology.

[6]  W. Wold,et al.  Increasing the Efficacy of Oncolytic Adenovirus Vectors , 2010, Viruses.

[7]  C. Barardi,et al.  Survival of adenovirus types 2 and 41 in surface and ground waters measured by a plaque assay. , 2011, Environmental science & technology.

[8]  J. Roth.  Adenovirus p53 gene therapy , 2006, Expert opinion on biological therapy.

[9]  D. Sze,et al.  Effects of Onyx-015 among metastatic colorectal cancer patients that have failed prior treatment with 5-FU/leucovorin , 2005, Cancer Gene Therapy.

[10]  M. Barry,et al.  Generation of a Kupffer cell-evading adenovirus for systemic and liver-directed gene transfer. , 2011, Molecular therapy : the journal of the American Society of Gene Therapy.

[11]  L. Jl,et al.  A phase I trial of intratumoral administration of recombinant oncolytic adenovirus overexpressing HSP70 in advanced solid tumor patients , 2009, Gene Therapy.

[12]  H. Rammensee,et al.  Ex vivo detection of adenovirus specific CD4+ T-cell responses to HLA-DR-epitopes of the Hexon protein show a contracted specificity of T(HELPER) cells following stem cell transplantation. , 2010, Virology.

[13]  R. Crystal,et al.  Analysis of risk factors for local delivery of low- and intermediate-dose adenovirus gene transfer vectors to individuals with a spectrum of comorbid conditions. , 2002, Human gene therapy.

[14]  K. Partanen,et al.  Immunological effects of low-dose cyclophosphamide in cancer patients treated with oncolytic adenovirus. , 2011, Molecular therapy : the journal of the American Society of Gene Therapy.

[15]  J. Hecht,et al.  A phase I/II trial of intratumoral endoscopic ultrasound injection of ONYX-015 with intravenous gemcitabine in unresectable pancreatic carcinoma. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

[16]  S. Buchbinder,et al.  Overview of STEP and Phambili trial results: two phase IIb test-of-concept studies investigating the efficacy of MRK adenovirus type 5 gag/pol/nef subtype B HIV vaccine , 2010, Current opinion in HIV and AIDS.

[17]  T. McDonnell,et al.  A mutant oncolytic adenovirus targeting the Rb pathway produces anti-glioma effect in vivo , 2000, Oncogene.

[18]  M. Ehlers,et al.  Prevalence of human adenoviruses in raw and treated water. , 2004, Water science and technology : a journal of the International Association on Water Pollution Research.

[19]  A. Venook,et al.  Biological activities of a recombinant adenovirus p53 (SCH 58500) administered by hepatic arterial infusion in a Phase 1 colorectal cancer trial , 2006, Cancer Gene Therapy.

[20]  A. Hemminki,et al.  Chapter eight--Oncolytic adenoviruses for cancer immunotherapy: data from mice, hamsters, and humans. , 2012, Advances in cancer research.

[21]  G. Lesage,et al.  Avidity Binding of Human Adenovirus Serotypes 3 and 7 to the Membrane Cofactor CD46 Triggers Infection , 2011, Journal of Virology.

[22]  G. Demers,et al.  Pharmacologic indicators of antitumor efficacy for oncolytic virotherapy. , 2003, Cancer research.

[23]  H. G. van der Poel,et al.  A phase I trial of CV706, a replication-competent, PSA selective oncolytic adenovirus, for the treatment of locally recurrent prostate cancer following radiation therapy. , 2001, Cancer research.

[24]  P. Seth,et al.  Clinical trial of E1B-deleted adenovirus (dl1520) gene therapy for hepatocellular carcinoma , 2002, Cancer Gene Therapy.

[25]  Adam Bagg,et al.  Fatal systemic inflammatory response syndrome in a ornithine transcarbamylase deficient patient following adenoviral gene transfer. , 2003, Molecular genetics and metabolism.

[26]  I. Tannock,et al.  A controlled trial of intratumoral ONYX-015, a selectively-replicating adenovirus, in combination with cisplatin and 5-fluorouracil in patients with recurrent head and neck cancer , 2000, Nature Medicine.

[27]  D. Kirn,et al.  Targeted genetic and viral therapy for advanced head and neck cancers. , 2009, Drug discovery today.

[28]  D. Curiel,et al.  Advanced generation adenoviral vectors possess augmented gene transfer efficiency based upon coxsackie adenovirus receptor-independent cellular entry capacity. , 2000, Cancer research.

[29]  D. Kirn,et al.  The dl1520 Virus Is Found Preferentially in Tumor Tissue after Direct Intratumoral Injection in Oral Carcinoma , 2004, Clinical Cancer Research.

[30]  Jing Chen,et al.  Oncolytic virus as an agent for the treatment of malignant ascites. , 2009, Cancer biotherapy & radiopharmaceuticals.

[31]  Yang Zhang,et al.  [Phase III randomized clinical trial of intratumoral injection of E1B gene-deleted adenovirus (H101) combined with cisplatin-based chemotherapy in treating squamous cell cancer of head and neck or esophagus]. , 2004, Ai zheng = Aizheng = Chinese journal of cancer.

[32]  N. Brunetti‐Pierri,et al.  Helper-dependent adenoviral vectors for liver-directed gene therapy. , 2011, Human molecular genetics.

[33]  Li Zhang,et al.  [Safety of an E1B deleted adenovirus administered intratumorally to patients with cancer]. , 2003, Ai zheng = Aizheng = Chinese journal of cancer.

[34]  R. Alemany,et al.  Verapamil results in increased blood levels of oncolytic adenovirus in treatment of patients with advanced cancer. , 2012, Molecular therapy : the journal of the American Society of Gene Therapy.

[35]  H. Fang,et al.  Clinical trials with oncolytic adenovirus in China. , 2007, Current cancer drug targets.

[36]  M. Kelly,et al.  E1B-deleted adenovirus (dl1520) gene therapy for patients with primary and secondary liver tumors. , 2001, Human gene therapy.

[37]  James W. MacDonald,et al.  Coagulation Factor X Activates Innate Immunity to Human Species C Adenovirus , 2012, Science.

[38]  N. Senzer,et al.  A review of contusugene ladenovec (Advexin) p53 therapy. , 2009, Current opinion in molecular therapeutics.

[39]  J. Nemunaitis,et al.  Head and neck cancer: Response to p53‐based therapeutics , 2011, Head & neck.

[40]  M. Sobsey,et al.  Efficacy of Hospital Germicides against Adenovirus 8, a Common Cause of Epidemic Keratoconjunctivitis in Health Care Facilities , 2006, Antimicrobial Agents and Chemotherapy.

[41]  T. Möller,et al.  Desmoglein 2 is a receptor for adenovirus serotypes 3, 7, 11, and 14 , 2010, Nature Medicine.

[42]  J. Nemunaitis,et al.  Intravenous infusion of a replication-selective adenovirus (ONYX-015) in cancer patients: safety, feasibility and biological activity , 2001, Gene Therapy.

[43]  Z. Ram,et al.  Adenovirus-mediated gene therapy with sitimagene ceradenovec followed by intravenous ganciclovir for patients with operable high-grade glioma (ASPECT): a randomised, open-label, phase 3 trial. , 2013, The Lancet. Oncology.

[44]  A. Ristimäki,et al.  Oncolytic adenovirus coding for granulocyte macrophage colony-stimulating factor induces antitumoral immunity in cancer patients. , 2010, Cancer research.

[45]  Y. Liu,et al.  A New Group B Adenovirus Receptor Is Expressed at High Levels on Human Stem and Tumor Cells , 2006, Journal of Virology.

[46]  J. Nemunaitis,et al.  Clinical development directions in oncolytic viral therapy , 2011, Cancer Gene Therapy.

[47]  D. Dhar,et al.  Oncolytic (replication-competent) adenoviruses as anticancer agents , 2010, Expert opinion on biological therapy.

[48]  Mani Menon,et al.  Phase I study of replication-competent adenovirus-mediated double suicide gene therapy for the treatment of locally recurrent prostate cancer. , 2002, Cancer research.

[49]  B. Mariñas,et al.  Effect of Exposure to UV-C Irradiation and Monochloramine on Adenovirus Serotype 2 Early Protein Expression and DNA Replication , 2008, Applied and Environmental Microbiology.

[50]  C. Wiethoff,et al.  Adenovirus Membrane Penetration Activates the NLRP3 Inflammasome , 2010, Journal of Virology.

[51]  A. Venook,et al.  Safety and feasibility of injection with an E1B-55 kDa gene-deleted, replication-selective adenovirus (ONYX-015) into primary carcinomas of the pancreas: a phase I trial , 2001, Gene Therapy.

[52]  R. Strauss,et al.  Anatomical and physical barriers to tumor targeting with oncolytic adenoviruses in vivo. , 2009, Current opinion in molecular therapeutics.

[53]  M. Gore,et al.  Phase I trial of intraperitoneal injection of the E1B-55-kd-gene-deleted adenovirus ONYX-015 (dl1520) given on days 1 through 5 every 3 weeks in patients with recurrent/refractory epithelial ovarian cancer. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[54]  K. Partanen,et al.  Oncolytic adenovirus with temozolomide induces autophagy and antitumor immune responses in cancer patients. , 2013, Molecular therapy : the journal of the American Society of Gene Therapy.

[55]  H. Ertl,et al.  New insights on adenovirus as vaccine vectors. , 2009, Molecular therapy : the journal of the American Society of Gene Therapy.

[56]  K. Partanen,et al.  Antiviral and Antitumor T-cell Immunity in Patients Treated with GM-CSF–Coding Oncolytic Adenovirus , 2013, Clinical Cancer Research.

[57]  B. Movsas,et al.  Prostate cancer gene therapy clinical trials. , 2007, Molecular therapy : the journal of the American Society of Gene Therapy.

[58]  Raymond D. Harris,et al.  A Phase I Study of a Tropism-Modified Conditionally Replicative Adenovirus for Recurrent Malignant Gynecologic Diseases , 2010, Clinical Cancer Research.

[59]  A. Pekosz,et al.  Prospects for oral replicating adenovirus-vectored vaccines. , 2013, Vaccine.

[60]  J. Nemunaitis,et al.  Pilot trial of intravenous infusion of a replication-selective adenovirus (ONYX-015) in combination with chemotherapy or IL-2 treatment in refractory cancer patients , 2003, Cancer Gene Therapy.

[61]  Zhao-hui Peng,et al.  Current status of gendicine in China: recombinant human Ad-p53 agent for treatment of cancers. , 2005, Human gene therapy.

[62]  Y. Guan,et al.  Transarterial injection of H101 in combination with chemoembolization overcomes recurrent hepatocellular carcinoma. , 2011, World journal of gastroenterology.

[63]  D. Sze,et al.  Minimal hepatic toxicity of Onyx-015: spatial restriction of coxsackie-adenoviral receptor in normal liver , 2006, Cancer Gene Therapy.

[64]  R. Warren,et al.  Intravascular adenoviral agents in cancer patients: Lessons from clinical trials , 2002, Cancer Gene Therapy.

[65]  J. S. St. George,et al.  Aerosol and lobar administration of a recombinant adenovirus to individuals with cystic fibrosis. I. Methods, safety, and clinical implications. , 2001, Human gene therapy.

[66]  D. Sze,et al.  Intra-arterial administration of a replication-selective adenovirus (dl1520) in patients with colorectal carcinoma metastatic to the liver: a phase I trial , 2001, Gene Therapy.

[67]  M. Ramachandra,et al.  Inefficient killing of quiescent human epithelial cells by replicating adenoviruses: potential implications for their use as oncolytic agents , 2005, Cancer Gene Therapy.

[68]  F. McCormick,et al.  Late viral RNA export, rather than p53 inactivation, determines ONYX-015 tumor selectivity. , 2004, Cancer cell.

[69]  Jie Zhou,et al.  Multiple hepatic arterial injections of recombinant adenovirus p53 and 5-fluorouracil after transcatheter arterial chemoembolization for unresectable hepatocellular carcinoma: a pilot phase II trial , 2009, Anti-cancer drugs.

[70]  L. Wein,et al.  Hepatic arterial infusion of a replication-selective oncolytic adenovirus (dl1520): phase II viral, immunologic, and clinical endpoints. , 2002, Cancer research.

[71]  K. Hostetler.  Alkoxyalkyl prodrugs of acyclic nucleoside phosphonates enhance oral antiviral activity and reduce toxicity: current state of the art. , 2009, Antiviral research.

[72]  J. Peabody,et al.  Phase I study of replication-competent adenovirus-mediated double-suicide gene therapy in combination with conventional-dose three-dimensional conformal radiation therapy for the treatment of newly diagnosed, intermediate- to high-risk prostate cancer. , 2003, Cancer research.

[73]  Juan Shi,et al.  An update on gene therapy in China. , 2009, Current opinion in molecular therapeutics.

[74]  K. Partanen,et al.  Ad3-hTERT-E1A, a fully serotype 3 oncolytic adenovirus, in patients with chemotherapy refractory cancer. , 2012, Molecular therapy : the journal of the American Society of Gene Therapy.

[75]  K. Partanen,et al.  Integrin targeted oncolytic adenoviruses Ad5‐D24‐RGD and Ad5‐RGD‐D24‐GMCSF for treatment of patients with advanced chemotherapy refractory solid tumors , 2012, International journal of cancer.

[76]  James M. Wilson.  Lessons learned from the gene therapy trial for ornithine transcarbamylase deficiency. , 2009, Molecular genetics and metabolism.

[77]  D. Curiel,et al.  Current issues and future directions of oncolytic adenoviruses. , 2010, Molecular therapy : the journal of the American Society of Gene Therapy.

[78]  E. Small,et al.  A phase I trial of intravenous CG7870, a replication-selective, prostate-specific antigen-targeted oncolytic adenovirus, for the treatment of hormone-refractory, metastatic prostate cancer. , 2006, Molecular therapy : the journal of the American Society of Gene Therapy.

[79]  B. Walker,et al.  Neutralizing Antibodies to Adenovirus Serotype 5 Vaccine Vectors Are Directed Primarily against the Adenovirus Hexon Protein1 , 2005, The Journal of Immunology.

[80]  L. Johnson,et al.  An adenovirus E1A mutant that demonstrates potent and selective systemic anti-tumoral efficacy , 2000, Nature Medicine.

[81]  A. Ristimäki,et al.  Prolonged systemic circulation of chimeric oncolytic adenovirus Ad5/3-Cox2L-D24 in patients with metastatic and refractory solid tumors , 2010, Gene Therapy.

[82]  D. Kirn,et al.  ONYX-015, an E1B gene-attenuated adenovirus, causes tumor-specific cytolysis and antitumoral efficacy that can be augmented by standard chemotherapeutic agents , 1997, Nature Medicine.

[83]  Holly Janes,et al.  Efficacy trial of a DNA/rAd5 HIV-1 preventive vaccine. , 2013, The New England journal of medicine.

[84]  M. Rudnicki,et al.  A helper-dependent adenovirus vector system: removal of helper virus by Cre-mediated excision of the viral packaging signal. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[85]  S. Wadler,et al.  Phase II clinical trial of intralesional administration of the oncolytic adenovirus ONYX-015 in patients with hepatobiliary tumors with correlative p53 studies. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

[86]  Jian-hua Chang,et al.  A phase I study of KH901, a conditionally replicating granulocyte-macrophage colony-stimulating factor: Armed oncolytic adenovirus for the treatment of head and neck cancers , 2009, Cancer biology & therapy.

[87]  J. Tschopp,et al.  Antiviral Antibodies Target Adenovirus to Phagolysosomes and Amplify the Innate Immune Response1 , 2009, The Journal of Immunology.

[88]  J. Tschopp,et al.  The inflammasome recognizes cytosolic microbial and host DNA and triggers an innate immune response , 2008, Nature.

[89]  Devan V Mehrotra,et al.  Efficacy assessment of a cell-mediated immunity HIV-1 vaccine (the Step Study): a double-blind, randomised, placebo-controlled, test-of-concept trial , 2008, The Lancet.

[90]  A. Hemminki,et al.  Oncolytic adenoviruses for the treatment of human cancer: focus on translational and clinical data. , 2011, Molecular pharmaceutics.

[91]  A. Leen,et al.  How I treat adenovirus in hematopoietic stem cell transplant recipients. , 2010, Blood.

[92]  P. Mithbaokar,et al.  SR-A and SREC-I are Kupffer and endothelial cell receptors for helper-dependent adenoviral vectors. , 2013, Molecular therapy : the journal of the American Society of Gene Therapy.

[93]  J. Nemunaitis,et al.  Oncolytic viral therapies , 2004, Cancer Gene Therapy.

[94]  J. Fueyo,et al.  Oncolytic adenoviruses for the treatment of brain tumors. , 2010, Current opinion in molecular therapeutics (Print).

[95]  D. Muruve,et al.  The innate immune response to adenovirus vectors. , 2004, Human gene therapy.

[96]  R. Alemany,et al.  Oncolytic Adenovirus ICOVIR-7 in Patients with Advanced and Refractory Solid Tumors , 2010, Clinical Cancer Research.

[97]  Stephen L. Brown,et al.  Second-generation replication-competent oncolytic adenovirus armed with improved suicide genes and ADP gene demonstrates greater efficacy without increased toxicity. , 2006, Molecular therapy : the journal of the American Society of Gene Therapy.

[98]  Xiaopei Huang,et al.  Innate Immune Response to Adenoviral Vectors Is Mediated by both Toll-Like Receptor-Dependent and -Independent Pathways , 2007, Journal of Virology.

[99]  J. Hamid,et al.  A Human Type 5 Adenovirus–Based Tuberculosis Vaccine Induces Robust T Cell Responses in Humans Despite Preexisting Anti-Adenovirus Immunity , 2013, Science Translational Medicine.

[100]  Matteo Pellegrini,et al.  Epigenetic Reprogramming by Adenovirus e1a , 2008, Science.

[101]  B. Mariñas,et al.  Mechanistic Aspects of Adenovirus Serotype 2 Inactivation with Free Chlorine , 2010, Applied and Environmental Microbiology.

[102]  K. Mansfield,et al.  Hexon-chimaeric adenovirus serotype 5 vectors circumvent pre-existing anti-vector immunity , 2006, Nature.

[103]  R. Crystal,et al.  Safety of local delivery of low- and intermediate-dose adenovirus gene transfer vectors to individuals with a spectrum of morbid conditions. , 2002, Human gene therapy.

[104]  Hepeng Jia,et al.  China offers alternative gateway for experimental drugs , 2006, Nature Biotechnology.

[105]  D. Sze,et al.  Dr. Gary J. Becker Young Investigator Award: intraarterial adenovirus for metastatic gastrointestinal cancer: activity, radiographic response, and survival. , 2003, Journal of vascular and interventional radiology : JVIR.

[106]  Lindsay J. Georgopoulos,et al.  Clinical adenoviral gene therapy for prostate cancer. , 2010, Human gene therapy.

[107]  W. Lu,et al.  Intra-tumor injection of H101, a recombinant adenovirus, in combination with chemotherapy in patients with advanced cancers: a pilot phase II clinical trial. , 2004, World journal of gastroenterology.

[108]  D. Curiel,et al.  Generation of recombinant adenovirus vectors with modified fibers for altering viral tropism , 1996, Journal of virology.

[109]  J. Roth,et al.  Biomarkers Predict p53 Gene Therapy Efficacy in Recurrent Squamous Cell Carcinoma of the Head and Neck , 2009, Clinical Cancer Research.

[110]  M. Gulley,et al.  A phase I study of Onyx-015, an E1B attenuated adenovirus, administered intratumorally to patients with recurrent head and neck cancer. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.

[111]  M. Tagawa,et al.  Gene medicine for cancer treatment: Commercially available medicine and accumulated clinical data in China , 2008, Drug design, development and therapy.

[112]  A. Hemminki,et al.  Oncolytic Virotherapy Trials—Letter , 2013, Clinical Cancer Research.